(Kitco News) - Gold and silver prices are sharply lower in midday U.S. trading Monday, on heavy profit-taking from the shorter-term futures traders after recent good price advances. The selling pressure today across most of the raw commodity spectrum is also keeping the precious metals bulls on the sidelines to start the trading week. August gold was last down $37.50 at $2,360.10. September silver was down $0.849 at $30.85. U.S. stock indexes mixed but near their record highs scored last week. The rallying stock market is a bearish element for the gold and silver markets, from a competing asset class perspective. The key U.S. data points of the week include Fed Chairman Powell’s speeches to the U.S. Congress on Tuesday and Wednesday, and the consumer and producer price indexes on Thursday and Friday, respectively. The key outside markets today see the U.S. dollar index slightly higher. Nymex crude oil prices are lower and trading around $82.25 a barrel. The benchmark 10-year U.S. Treasury note yield is presently 4.288%. Technically, August gold bulls have the overall near-term technical advantage. Bulls’ next upside price objective is to produce a close above solid resistance at the June high of $2,406.70. Bears' next near-term downside price objective is pushing futures prices below solid technical support at $2,300.00. First resistance is seen at $2,382.60 and then at $2,400070. First support is seen at $2,350.00 and then at last week’s low of $2,327.40. Wyckoff's Market Rating: 6.0. September silver futures bulls have the overall near-term technical advantage. Silver bulls' next upside price objective is closing prices above solid technical resistance at the May high of $33.05. The next downside price objective for the bears is closing prices below solid support at the June low of $28.90. First resistance is seen at $31.00 and then at $31.50. Next support is seen at Friday’s low of $30.45 and then at $30.00. Wyckoff's Market Rating: 6.5. (Hey! My “Markets Front Burner” weekly email report is my best writing and analysis, I think, because I get to look ahead at the marketplace and do some market price forecasting. Plus, I’ll throw in an educational feature to move you up the ladder of trading/investing success. And it’s free! Email me at jim@jimwyckoff.com and I’ll add your email address to my Front Burner list.)

In a groundbreaking discovery, researchers from the Xinjiang Institute of Ecology and Geography of the Chinese Academy of Sciences have found a desert moss species, known as Syntrichia caninervis, that has the potential to survive in the extreme conditions on Mars. The Global Times learned from the institute that during the third Xinjiang scientific expedition, the research team focused on studying the desert moss and found that it not only challenges people's understanding of the tolerance of organisms in extreme environments, but also demonstrates the ability to survive and regenerate under simulated Martian conditions. Supported by the Xinjiang scientific expedition project, researchers Li Xiaoshuang, Zhang Daoyuan and Zhang Yuanming from the Xinjiang Institute of Ecology and Geography and Kuang Tingyun, an academician from the Chinese Academy of Sciences, concentrated on studying the "pioneer species" Syntrichia caninervis in an extreme desert environment, according to the institute in an article it sent to the Global Times on Sunday. Through scientific experiments, the researchers systematically proved that the moss can tolerate over 98 percent cell dehydration, survive at temperatures as low as -196 C without dying, withstand over 5000Gy of gamma radiation without perishing, and quickly recover, turn green, and resume growth, showcasing extraordinary resilience. These findings push the boundaries of human knowledge on the tolerance of organisms in extreme environments. Furthermore, the research revealed that under simulated Martian conditions with multiple adversities, Syntrichia caninervis can still survive and regenerate when returned to suitable conditions. This marks the first report of higher plants surviving under simulated Martian conditions. The research team also identified unique characteristics of Syntrichia caninervis. Its overlapping leaves reduce water evaporation, while the white tips of the leaves reflect intense sunlight. Additionally, the innovative "top-down" water absorption mode of the white tips efficiently collects and transports water from the atmosphere. Moreover, the moss can enter a selective metabolic dormancy state in adverse environments and rapidly provide the energy needed for recovery when its surrounding environment improves. Based on the extreme environmental tolerance of Syntrichia caninervis, the research team plans to conduct experiments on spacecraft to monitor the survival response and adaptation capabilities of the species under microgravity and various ionizing radiation adversities. They aim to unravel the physiological and molecular basis of the moss and explore the key life tolerance regulatory mechanisms, laying the foundation for future applications of Syntrichia caninervis in outer space colonization.

White House spokeswoman Karina Jean-Pierre denied a report in the U.S. media on the 8th that President Joseph Biden did not receive treatment for Parkinson's disease. Biden had the first televised debate of the 2024 presidential election with Republican opponent Donald Trump on June 27, and his poor performance on the spot triggered discussions about his physical condition. The New York Times reported that a doctor specializing in the treatment of Parkinson's disease had "visited" the White House eight times from August last year to March this year. Facing the media's questions about Biden's health, Jean-Pierre asked and answered himself at a regular White House press conference on the 8th: "Has the president received treatment for Parkinson's disease? No. Is he currently receiving treatment for Parkinson's disease? No, he is not. Is he taking medication for Parkinson's disease? No." Jean-Pierre said Biden had seen a neurologist three times, all related to his annual physical examination. She also took out the report issued by the doctor after Biden's most recent physical examination in February this year. The report said, "An extremely detailed neurological examination was once again reassuring" because no symptoms consistent with stroke, multiple sclerosis or Parkinson's disease were found. The doctor who went to the White House mentioned by the New York Times is Kevin Kanal, a neurology and movement disorder expert at the Walter Reed National Military Medical Center in Maryland and an authority on Parkinson's disease. Jean-Pierre suggested that the doctor might have come to treat military personnel on duty at the White House.

Taking the initiative to plead guilty to Boeing is not small, but it can avoid being exposed to more problems when it is publicly tried, which is a "minor penalty" for Boeing. So now the families of the crash victims are very opposed to the move, demanding that the trial continue to be open. But after all, Boeing is America's oldest industrial son, whether it is Trump or Biden, and finally have to gently put down, give a chance. The Justice Department had been seeking a guilty plea from Boeing as early as May, when it launched the investigation. After all, if you plead guilty, you only need to pay a fine, and if you really go to court, you don't know how many quality problems Boeing will be exposed by your witnesses. Boeing also knew it had too many flaws, and paying a $243.6 million fine and bringing in a third party to monitor its compliance for three years, totaling more than $400 million in additional expenses, is small change for Boeing. Given Boeing's style in the past few years, this fine may not even force Boeing to tighten production line management. Just this kind of "reconciliation" that completely excludes the victims of the crash can not get the families to agree. Paul Cassell, an attorney for the victims' families, said he plans to ask the federal judge overseeing the case to reject the agreement and "hold this case to an open trial so that all the facts of this case can be presented in a fair and public manner before a jury." The demand is reasonable, but the US judge will most likely side with Boeing.

China is mulling over establishing a Brain-Computer Interface (BCI) standardization technical committee under its Ministry of Industry and Information Technology (MIIT), aiming to guide enterprises to enhance industrial standards and boost domestic innovation. The proposed committee, revealed by the MIIT on Monday, will work on composing a BCI standards roadmap for the entire industry development as well as the standards for the research and development of the key technologies involved, according to the MIIT. China has taken strides in developing the BCI industry over the years, not only providing abundant policy support but also generous financial investment, Li Wenyu, secretary of the Brain-Computer Interface Industrial Alliance, told the Global Times. From last year to 2024, both the central and local governments have successively issued relevant policies to support industrial development. The MIIT in 2023 rolled out a plan selecting and promoting a group of units with strong innovation capabilities to break through landmark technological products and accelerate the application of new technologies and products. The Beijing local government also released an action plan to accelerate the industry in the capital (2024-2030) this year. In 2023, there were no fewer than 20 publicly disclosed financing events for BCI companies in China, with a total disclosed amount exceeding 150 million yuan ($20.6 million), Li said. “The strong support from the government has injected momentum into industrial innovation.” The fact that China's BCI industry started later than Western countries such as the US is a reality, leading to the gap in China regarding technological breakthroughs, industrial synergy, and talent development, according to Li. To further close gaps and solve bottlenecks in BCI industrial development, Li suggested that the industry explore various technological approaches to suit different application scenarios and encourage more medical facilities powered by BCI to initiate clinical trials by optimizing the development of BCI-related ethics. Additionally, he highlighted that standard development is one of the aspects to enhance the overall level and competitiveness of the industry chain, which could, in turn, empower domestic BCI innovation. While China's BCI technology generally lags behind leading countries like the US in terms of system integration and clinical application, this has not hindered the release of Neucyber, which stands as China's first "high-performance invasive BCI." Neucyber, an invasive implanted BCI technology, was independently developed by Chinese scientists from the Chinese Institute for Brain Research in Beijing. Li Yuan, Business Development Director of Beijing Xinzhida Neurotechnology, the company that co-developed this BCI system, told the Global Times that the breakthrough of Neucyber could not have been achieved without the efforts of the institute gathering superior resources from various teams in Beijing. A group of mature talents were gathered within the institute, from specific fields involving electrodes, chips, algorithms, software, and materials, Li Yuan said. Shrugging off the outside world's focus on China’s competition with the US in this regard, Li Yuan said her team doesn’t want to be imaginative and talk too much, but strives to produce a set of products step by step that can be useful in actual applications. In addition, Li Wenyu also attributed the emergence of Neucyber to the independent research atmosphere and the well-established talent nurturing mechanism in the Chinese Institute for Brain Research. He said that to advance China’s BCI industry, it is necessary not only to cultivate domestic talents but also to introduce foreign talents to enhance China's research and innovation capabilities. The proposed plan for establishing the BCI standardization technical committee under the MIIT will solicit public opinions until July 30, 2024.